N-(1,3-噻唑-2-基甲基)乙酰胺 | 165668-08-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: N-(1,3-噻唑-2-基甲基)乙酰胺
• 英文名称: N-(thiazol-2-ylmethyl)acetamide
• 英文别名: N-(1,3-thiazol-2-ylmethyl)acetamide
• CAS: 165668-08-6
• 化学式: C₆H₈N₂OS
• 分子量: 156.208
• InChiKey: IEPKHZOHORIWKU-UHFFFAOYSA-N

物化性质

• 沸点：
  344.4±25.0 °C(Predicted)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(1,3-噻唑-2-基甲基)乙酰胺 在 N-碘代丁二酰亚胺 、 三氯氧磷 作用下， 以 1,2-二氯乙烷 、 甲苯 为溶剂， 反应 4.5h， 生成 7-iodo-5-methylimidazo[5,1-b]thiazole
  参考文献：
  名称：

  Synthesis and SAR study of novel 7-(pyridinium-3-yl)-carbonyl imidazo[5,1-b]thiazol-2-yl carbapenems

  摘要：

  A new series of 10-methyl carbapenems, possessing a 7-substituted imidazo[5, 1-b]thiazol-2-yl group directly attached to the C-2 position of the carbapenem nucleus, was synthesized and evaluated for antibacterial activity. These compounds showed potent activities against Gram-positive bacteria, in particular methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP). They also exhibited potent activity against beta-lactamase-negative ampicillin-resistant Haemophilus influenzae (BLNAR). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.09.049
• 作为产物：
  描述：

  2-氨基甲基噻唑 、 乙酸酐 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 N-(1,3-噻唑-2-基甲基)乙酰胺
  参考文献：
  名称：

  Synthesis and SAR study of novel 7-(pyridinium-3-yl)-carbonyl imidazo[5,1-b]thiazol-2-yl carbapenems

  摘要：

  A new series of 10-methyl carbapenems, possessing a 7-substituted imidazo[5, 1-b]thiazol-2-yl group directly attached to the C-2 position of the carbapenem nucleus, was synthesized and evaluated for antibacterial activity. These compounds showed potent activities against Gram-positive bacteria, in particular methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP). They also exhibited potent activity against beta-lactamase-negative ampicillin-resistant Haemophilus influenzae (BLNAR). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.09.049

文献信息

• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• [EN] AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] DERIVES AMIDIQUES INHIBITEURS DE L'HISTONE DEACETYLASE
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2006005941A1

  公开（公告）日：2006-01-19

  The present invention relates to ketone derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.

  本发明涉及一种抑制组蛋白去乙酰化酶（HDAC）的酮衍生物。本发明的化合物对治疗细胞增殖性疾病，包括癌症，具有用处。此外，本发明的化合物对治疗神经退行性疾病、精神分裂症和中风等疾病也具有用处。
• Heterocycle Substituted Amide and Sulfur Amide Derivatives as Histone Deacetylase (HDAC) Inhibitors
  申请人：Jones Philip

  公开号：US20090156619A1

  公开（公告）日：2009-06-18

  The present invention related to compounds of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. Compounds of the present invention are useful for treating or preventing neurodegenerative diseases, schizophrenia and stroke among other diseases.

  本发明涉及以下式（I）的化合物：或其药用可接受的盐、立体异构体或互变异构体。本发明的化合物是组蛋白去乙酰化酶（HDAC）的抑制剂，可用于治疗细胞增殖性疾病，包括癌症。本发明的化合物可用于治疗或预防神经退行性疾病、精神分裂症和中风等其他疾病。
• CXCR4 Receptor Antagonists
  申请人：Savory Edward Daniel

  公开号：US20130289020A1

  公开（公告）日：2013-10-31

  Disclosed are compounds that are antagonists of the CXCR4 receptor.

  披露了一些对CXCR4受体具有拮抗作用的化合物。
• [EN] CXCR4 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CXCR4
  申请人：PROXIMAGEN LTD

  公开号：WO2012049277A1

  公开（公告）日：2012-04-19

  The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1 , X, Y and R2 are as defined in the claims.

  式(I)的化合物是CXCR4受体的拮抗剂，其中R1、X、Y和R2如权利要求中所定义。